Emerald Mutual Fund Advisers Trust Has $2.32 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Emerald Mutual Fund Advisers Trust boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1,776.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,100 shares of the biotechnology company's stock after purchasing an additional 18,082 shares during the period. Emerald Mutual Fund Advisers Trust's holdings in Sarepta Therapeutics were worth $2,322,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. World Investment Advisors LLC purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $2,418,000. Tidal Investments LLC grew its holdings in Sarepta Therapeutics by 91.2% in the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock valued at $704,000 after purchasing an additional 2,688 shares during the period. Garden State Investment Advisory Services LLC acquired a new position in Sarepta Therapeutics during the third quarter worth approximately $2,115,000. GAMMA Investing LLC raised its stake in Sarepta Therapeutics by 27.7% during the fourth quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 185 shares during the period. Finally, Everence Capital Management Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $344,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.70% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on SRPT. Wells Fargo & Company initiated coverage on Sarepta Therapeutics in a report on Friday, April 11th. They issued an "overweight" rating and a $115.00 target price on the stock. Royal Bank of Canada cut shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Morgan Stanley dropped their price objective on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research report on Friday, April 11th. Cantor Fitzgerald restated an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.70.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded up $0.73 during mid-day trading on Friday, reaching $63.51. 1,395,787 shares of the company traded hands, compared to its average volume of 1,427,144. The stock has a fifty day simple moving average of $73.73 and a 200-day simple moving average of $104.12. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market cap of $6.24 billion, a PE ratio of 50.81 and a beta of 0.93. Sarepta Therapeutics, Inc. has a fifty-two week low of $48.01 and a fifty-two week high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.